why choose us

First received: October 09, 2023

Clinical Trial: Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Study Status: Completed

Recruit Status: RECRUITING

Condition: Ovarian Cancer

Study Type: INTERVENTIONAL


Official Title: Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Fr

Brief Summary: To find out if combining pembrolizumab, bevacizumab (or an equivalent biosimilar drug), and low-dose cyclophosphamide can help control high-grade ovarian cancer that has MRD after treatment.The safety of this treatment combination will also be studied.

Read more